The Patent Finder

Shanghai Syncores Technologies Inc. Ltd.

15 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 25, 2026
    The maintenance fee for Preparation methods for palbociclib free base crystal form A and crystal form B (US 10,329,290) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
  • 1 fee due Feb 20, 2027
    The maintenance fee for Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor (US 10,385,079) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
  • 1 fee due Mar 8, 2027
    The maintenance fee for Method for synthesizing rivaroxaban intermediate, 4-(4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazoligdin-3-YL]phenyl)morpholin-3-one (US 9,126,990) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,126,990Method for synthesizing rivaroxaban intermediate, 4-(4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazoligdin-3-YL]phenyl)morpholin-3-one
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,656,958Method for synthesizing key intermediate of apixaban
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,745,264Method for preparing silodosin and intermediate thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,926,286Vortioxetine intermediate and synthesis process thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,951,036Method for preparing canagliflozin intermediate 2-(2-methyl-5-bromobenzyl)-5-(4-fluorophenyl)thiophene
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,189,760Method for preparing sitagliptin intermediate via asymmetrical reduction method
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,329,290Preparation methods for palbociclib free base crystal form A and crystal form B
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,385,079Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,766,895Preparation methods for palbociclib free base crystal form A and crystal form B
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,836,751Methods for Preparing Nintedanib and Intermediates Thereof
In force
 · High confidence
In forceHigh confidence
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited